Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules

Therapeutic Delivery

Volumn 1, Issue 6, 2010, Pages 775-784

  Mittapalli, Rajendar K ^a   Manda, Vamshi K ^a   Adkins, Chris E ^a   Geldenhuys, Werner J ^b   Lockman, Paul R ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; CETIRIZINE; CYPROHEPTADINE; DRUG CARRIER; KETOTIFEN; MELPHALAN; MEVINOLIN; N(G) NITROARGININE METHYL ESTER; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PHENYLALANINE; PRAVASTATIN; SIMVASTATIN;

BLOOD BRAIN BARRIER; BRAIN PERFUSION; COMPUTER AIDED DESIGN; COMPUTER MODEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; MOLECULE; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TIGHT JUNCTION; VASCULAR ENDOTHELIUM;

EID: 79954506893     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.76     Document Type: Review

References (62)

1. Pardridge WM. Drug targeting to the brain. Pharm. Res. 24(9), 1733-1744 (2007).
2. Pardridge WM. Blood-brain barrier delivery. Drug Discov. Today 12(1-2), 54-61 (2007). (Pubitemid 46014479)
3. Oku T, Tjuvajev JG, Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 58(18), 4185-4192 (1998). (Pubitemid 28440578)
4. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 54(1), 131-142 (2004). (Pubitemid 38040866)
5. Smith QR. A review of blood-brain barrier transport techniques. Methods Mol. Med. 89, 193-208 (2003).
6. Crone C, Olesen PS. Electrical resistance of brain microvascular endothelium. Brain Res. 241(1), 49-55 (1982). (Pubitemid 12124928)
7. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161(3), 653-660 (2003). (Pubitemid 36578587)
8. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 20(1), 57-76 (2000). (Pubitemid 30090916)
9. Huber JD Egleton DR, Davis PT. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24(12), 719-725 (2001). (Pubitemid 33097539)
10. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol. 20(2), 217-230 (2000). (Pubitemid 30091457)
11. Howles GP, Bing KF, Qi Y, Rosenzweig SJ, Nightingale KR, Johnson GA. Contrastenhanced in vivo magnetic resonance microscopy of the mouse brain enabled by noninvasive opening of the blood-brain barrier with ultrasound. Magn. Reson. Med. 64(4), 995-1004 (2010).
12. Minn A, Ghersi-Egea JF, Perrin R, Leininger B, Siest G. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res. Brain Res. Rev. 16(1), 65-82 (1991).
13. Loscher W, Potschka H, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76(1), 22-76 (2005). (Pubitemid 41033402)
14. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221(6), 1629-1639 (1971).
15. Tamai, I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89(11), 1371-1388 (2000).
16. Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 36(2-3), 277-290 (1999). (Pubitemid 29121976)
17. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 31(6), 246-254 (2010).
18. Allen DD, Lockman RP. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci. 73(13), 1609-1615 (2003). (Pubitemid 36869002)
19. Kusuhara, H, Sugiyama Y, Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2(1), 73-85 (2005). (Pubitemid 40128028)
20. Smith QR, Stoll J. Blood-brain barrier amino acid transport. In: Introduction to Blood-Brain Barrier. Pardridge MW (Ed.). Cambridge University Press, Cambridge, UK (1998).
21. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11(2), 305-311 (1994). (Pubitemid 24076229)
22. Tsuji A, Saheki A, Tamai I, Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J. Pharmacol. Exp. Ther. 267(3), 1085-1090 (1993). (Pubitemid 24068669)
23. Adkison KD, Shen DD. Uptake of valproic acid into rat brain is mediated by a mediumchain fatty acid transporter. J. Pharmacol. Exp. Ther. 276(3), 1189-1200 (1996).
24. Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 40(5), 385-403 (2010).
25. Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci. 8(3), 311-321 (2006). (Pubitemid 44682748)
26. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by l-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharmacol. 61(4), 729-737 (2002). (Pubitemid 34273151)
27. Takada Y, Vistica DT, Greig NH, Purdon D, Rapoport SI, Smith QR. Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res. 52(8), 2191-2196 (1992).
28. Matharu J, Oki J, Worthen DR, Smith QR, Crooks PA. Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier. Bioorg. Med. Chem. Lett. 20(12), 3688-3691 (2010).
29. Sekine T Cha HS, and Endou H, The multispecific organic anion transporter (OAT) family. Pflugers Arch. 440(3), 337-350 (2000). (Pubitemid 30445708)
30. Ahn SY, Eraly SA, Tsigelny I, Nigam SK. Interaction of organic cations with organic anion transporters. J. Biol. Chem. 284(45), 31422-31430 (2009).
31. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res. 18(9), 1262-1269 (2001). (Pubitemid 32846318)
32. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273(1), 251-260 (2000). (Pubitemid 30426895)
33. Schmitt BM, Gorbunov D, Schlachtbauer P. Charge-to-substrate ratio during organic cation uptake by rat OCT2 is voltage dependent and altered by exchange of glutamate 448 with glutamine. Am. J. Physiol. Renal Physiol. 296(4), F709-F722 (2009).
34. Koepsell H Schmitt MB, Gorboulev V. Organic cation transporters. Rev. Physiol. Biochem. Pharmacol. 150, 36-90 (2003).
35. Moaddel R, Ravichandran S, Bighi F, Yamaguchi R, Wainer IW. Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Br. J. Pharmacol. 151(8), 1305-1314 (2007). (Pubitemid 47255908)
36. Yamazaki M, Terasaki T, Yoshioka K, et al. Carrier-mediated transport of H1-antagonist at the blood-brain barrier: a common transport system of H1-antagonists and lipophilic basic drugs. Pharm. Res. 11(11), 1516-1518 (1994). (Pubitemid 24339666)
37. Yamazaki M, Terasaki T, Yoshioka K, et al. Carrier-mediated transport of H1-antagonist at the blood-brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primary monolayer cultures. Pharm. Res. 11(7), 975-978 (1994). (Pubitemid 24227641)
38. Lockman PR, Allen DD. The transport of choline. Drug Dev. Ind. Pharm. 28(7), 749-771 (2002). (Pubitemid 34977794)
39. Allen DD, Smith RQ. Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem. 76(4), 1032-1041 (2001). (Pubitemid 32167376)
40. Allen DD, Smith RQ. Blood-brain barrier choline transport in the senescent rat. Neurosci. Lett. 277(3), 198-202 (1999).
41. Klein J, Köppen A, Löffelholz K, Schmitthenner J. Uptake and metabolism of choline by rat brain after acute choline administration. J. Neurochem. 58(3), 870-876 (1992).
42. Smith QR, Takasato Y, Sweeney DJ, Rapoport SI. Regional cerebrovascular transport of leucine as measured by the in situ brain perfusion technique. J. Cereb. Blood Flow Metab. 5(2), 300-311 (1985). (Pubitemid 15123218)
43. Smith QR, Takasato Y, Rapoport IS. Kinetic analysis of l-leucine transport across the blood-brain barrier. Brain Res. 311(1), 167-170 (1984). (Pubitemid 14020814)
44. Takasato Y, Rapoport IS, Smith RQ. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247(3 Pt2), H484-H493 (1984). (Pubitemid 14047362)
45. Lockman PR, Roder EK, Allen DD. Inhibition of the rat blood-brain barrier choline transporter by manganese chloride. J. Neurochem. 79(3), 588-594 (2001). (Pubitemid 33029932)
46. Dwoskin LP, Wooters TE, Sumithran SP, et al. N,N′-Alkane-diyl-bis- 3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J. Pharmacol. Exp. Ther. 326(2), 563-576 (2008).
47. Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP, Crooks PA. bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 18(20), 5622-5625 (2008).
48. Geldenhuys WJ, Lockman PR, Nguyen TH, et al. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg. Med. Chem. 13(13), 4253-4261 (2005). (Pubitemid 40779395)
49. Geldenhuys WJ, Manda VK, Mittapalli RK, et al. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(3), 870-877 (2010).
50. Lockman PR, Manda PK, Geldenhuys WJ, et al. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist N,N-dodecylbispicolinium dibromide at the blood-brain barrier. J. Pharmacol. Exp. Ther. 324(1), 244-250 (2008). (Pubitemid 350294176)
51. Zheng G, Zhang Z, Lockman PR, et al. Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(11), 3208-3210 (2010).
52. Deuther-Conrad W, Patt JT, Lockman PR, et al. Norchloro-fluoro- homoepibatidine (NCFHEB) -a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur. Neuropsychopharmacol. 18(3), 222-229 (2008).
53. Allen DD, Geldenhuys WJ. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci. 78(10), 1029-1033 (2006). (Pubitemid 43143457)
54. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21(57), 8786-8803 (2002). (Pubitemid 36132400)
55. Chang C Ray A, Swaan P. In silico strategies for modeling membrane transporter function. Drug Discov. Today 10(9), 663-671 (2005). (Pubitemid 40704774)
56. Geldenhuys WJ, Allen DD, Lockman RP. 3-D-QSAR and docking studies on the neuronal choline transporter. Bioorg. Med. Chem. Lett. 20(16), 4870-4877 (2010).
57. Allen DD, Lockman PR, Roder KE, Dwoskin LP, Crooks PA. Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J. Pharmacol. Exp. Ther. 304(3), 1268-1274 (2003). (Pubitemid 36254440)
58. Geldenhuys WJ, Lockman PR, McAfee JH, Fitzpatrick KT, Van der Schyf CJ, Allen DD. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 14(12), 3085-3092 (2004). (Pubitemid 38624568)
59. Geldenhuys WJ, Manda VK, Mittapalli RK, et al. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(3), 870-877 (2010).
60. Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg J. Predicting the three-dimensional structure of the human facilitative glucose transporter glut 1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys. J. 87(5), 2990-2999 (2004). (Pubitemid 40468559)
61. Bednarczyk D, Ekins S, Wikel JH, Wright SH. Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol. Pharmacol. 63(3), 489-498 (2003). (Pubitemid 36297318)
62. Mehdipour AR, Hamidi M. Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov. Today 14(21-22), 1030-1036 (2009).